Evidence map›Paper›PMID 28418523›Full record

ArticleJAMA neurology2017

Neurocognitive Trajectory of Boys Who Received a Hematopoietic Stem Cell Transplant at an Early Stage of Childhood Cerebral Adrenoleukodystrophy.

Elizabeth I Pierpont, Julie B Eisengart, Ryan Shanley, David Nascene, Gerald V Raymond, Elsa G Shapiro, Rich S Ziegler, Paul J Orchard, Weston P Miller

Open access · bronzeAbstract read
In one paragraph

Article in JAMA neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Leukodystrophy Imaging: Insights for Diagnostic Dilemmas.Medical sciences (Basel, Switzerland) · 2024
    Review
  11. Review
  12. Article
  13. Sex-specific newborn screening for X-linked adrenoleukodystrophy.Journal of inherited metabolic disease · 2023
    Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Elizabeth I PierpontDivision of Clinical Behavioral Neuroscience, Department of Pediatrics, University of Minnesota, Minneapolis.
Julie B EisengartDivision of Clinical Behavioral Neuroscience, Department of Pediatrics, University of Minnesota, Minneapolis.
Ryan ShanleyBiostatistics and Bioinformatics Core, University of Minnesota Masonic Cancer Center, Minneapolis.
David NasceneDepartment of Radiology, University of Minnesota, Minneapolis.
Gerald V RaymondDepartment of Neurology, University of Minnesota, Minneapolis.
Elsa G ShapiroDivision of Clinical Behavioral Neuroscience, Department of Pediatrics, University of Minnesota, Minneapolis5Shapiro & Delaney LLC, University of Minnesota, Minneapolis.
Rich S ZieglerDivision of Clinical Behavioral Neuroscience, Department of Pediatrics, University of Minnesota, Minneapolis.
Paul J OrchardDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis.
Weston P MillerDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis.
University of Minnesota · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
NCATS NIH HHS UL1 TR000114NCATS NIH HHS UL1 TR002494
6 · The paper itself

Abstract

Importance: Untreated childhood cerebral adrenoleukodystrophy (cALD) is a fatal disease associated with progressive cerebral demyelination and rapid, devastating neurologic decline. The standard of care to enhance long-term survival and stabilize cerebral disease is a hematopoietic stem cell transplant (HSCT). Neurologic outcomes are better when HSCT occurs at an earlier stage of cALD, yet there is limited understanding of the neurocognitive trajectory of patients who undergo HSCT. Objectives: To characterize neurocognitive outcomes of boys with cALD and early-stage cerebral disease who were treated with an allogeneic HSCT and to identify disease- and treatment-related factors associated with long-term functioning. Design, Setting, and Participants: Baseline and follow-up neurocognitive test performance was analyzed for all boys with cALD who received an HSCT at the University of Minnesota between January 1, 1991, and October 20, 2014, and who had a pretransplant magnetic resonance imaging (MRI) severity score of less than 10 (scale range, 0-34; higher scores indicate greater severity). Main Outcomes and Measures: Longitudinal neurocognitive test performance in 4 domains (verbal comprehension, perceptual [visual] reasoning, working memory, and processing speed) were the primary outcome measures. Secondary analysis at the most recent evaluation also included measures of sustained attention, verbal memory, visual-motor integration, and fine motor function. Results: Among the 62 boys in this study (mean [SD] age at transplant, 8.37 [2.80] years; range, 4-16 years), there was a significant association of pretransplant MRI severity and baseline verbal comprehension (r = -0.340; P = .008), perceptual reasoning (r = -0.419; P = .001), and processing speed (r = -0.285; P = .03) scores. Higher pretransplant MRI severity scores were also associated with a steeper decline in neurocognitive functioning during the 5-year follow-up period. Twenty-two of 33 patients (67%) with available long-term follow-up neurocognitive testing had severe impairment in at least 1 neurocognitive domain at the most recent evaluation. Conclusions and Relevance: Boys with cALD who have greater than minimal cerebral disease detected on MRI scans at the time of an HSCT are at risk for severe, persistent neurocognitive deficits. These findings motivate further exploration of methods of detecting cerebral disease prior to development of lesions observable on MRI scans, an endeavor that may be facilitated by newborn screening for adrenoleukodystrophy. These findings may serve a benchmark role in evaluating the efficacy of novel interventions for cALD.

Indexed as

Severity of Illness IndexAdolescentAdolescent DevelopmentAdrenoleukodystrophyChildChild DevelopmentChild, PreschoolCognitive DysfunctionFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansMagnetic Resonance ImagingMaleNeuropsychological TestsTreatment Outcome

Identifiers

PMID28418523
PMCPMC5540007
OpenAlexW2606346746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.